31 results about "Arthritis therapy" patented technology

An objective of the present invention is to provide a therapeutic agent for treating rheumatoid arthritis, juvenile rheumatoid arthritis, macrophage activation syndrome, septicemia, and FR-β expressing leukemia, which induces apoptosis in activated macrophages and folate receptor beta (FR-β) expressing leukemia cells to specifically destroy these cells. An FR-β monoclonal antibody of the present invention is preferably an IgG-type monoclonal antibody which specifically reacts with a human-type FR-β antigen and is produced from a clone resulting from immunization with an FR-β expressing B300-19 cell. The FR-β monoclonal antibody of the present invention specifically reacts with the FR-β antigen of activated macrophages and FR-β expressing leukemia cells and a therapeutic agent of the present invention contains an FR-β antibody immunotoxin which causes apoptosis in activated macrophages and FR-β expressing leukemia cells, as an active ingredient. Further, suitable administration form for the therapeutic agent of the present invention includes intravenous injection as well as joint injection in the case of therapeutic agents for rheumatoid arthritis and juvenile arthritis.

This invention provides a new therapeutic or prophylactic agent for arthritis such as osteoarthritis. Specifically, it provides a therapeutic or prophylactic agent for arthritis such as osteoarthritis, or an agent for promoting the growth of articular chondrocyte, comprising a guanyl cyclase B (GC-B) activator as an active ingredient; or a method for inhibiting arthritis or for promoting the growth of articular chondrocyte by activating GC-B; or a method for screening an agent for promoting the growth of articular chondrocyte or an agent capable of treating arthritis using the GC-B activity as an indication.

A method and composition for treating osteoarthritis with ion-channel regulators is disclosed. The ion-channel regulators are used alone or in combination with other osteoarthritis treatment agents, including but not limited to injectable agents such as viscosupplements and steroids. A composition comprising one or more ion-channel regulator(s) and one or more osteoarthritis treatment agent(s) is also disclosed.

The invention discloses ultrasonic microbubbles for treating arthritis and a use thereof. The microbubbles contain gene plasmids capable of expressing tumor necrosis factor receptor (TNFR) protein, wherein the gene plasmids are adsorbed to the surface of the microbubbles and/or packaged in the microbubbles; the gene plasmids are expression plasmids; the gene plasmids of the tumor necrosis factor receptor protein contain extracellular domain gene of the tumor necrosis factor receptor (TNFR) or contain gene segment of the protein or peptide fragment, which can be combined with a tumor necrosis factor (TNF); and the gene plasmids express soluble protein or peptide fragment which can prevent the tumor necrosis factor from combining with the tumor necrosis factor receptor on a cell membrane after transfecting the body cells. The ultrasonic microbubbles are not only low in manufacturing cost for greatly relieving the economic burden of the patients and families, but also have breakthrough development in the field of treating anthritis, and can be extensively popularized and used in the field.

The present invention relates to a composition of a stem cell-derived exosome-containing culture for preventing or treating arthritis and, more particularly, to a pharmaceutical composition comprisinga stem cell-derived exosome-containing culture as an effective ingredient for preventing or treating arthritis, wherein the stem cell-derived exosome-containing culture is obtained by treating a stemcell culture with TNF-[alpha] and incubating the stem cell culture in the condition of a 1-8 % oxygen concentration. Containing a large amount of exosomes containing functional effective ingredientssuch as a cartilage regeneration promoting factor, etc., the stem cell-derived exosome-containing culture according to the present invention was found to have a far higher therapeutic effect on arthritis, compared to conventional stem cell transplantation methods for treatment of arthritis and the application of cultures obtained in general stem cell culturing conditions. Hence, the stem cell-derived exosome-containing culture according to the present invention has the effect of being available as a new therapeutic agent for effective treatment of arthritis.

A physiotherapy instrument for human facet joint inflammation, which relates to the technical field of medical treatment equipment, includes a hard treatment cavity and a negative pressure generation control system, and at least one opening for limbs to extend in and out is provided on the treatment cavity, and the The treatment chamber is connected with a negative pressure generation control system through the airway. The treatment chamber is L-shaped, and can be used for limbs to be placed after bending part or all of the thigh with the knee up and the calf with the knee down, and for the elbow to go up. A part of the arm and a part or all of the lower bladder from the elbow are bent and put in; the L-shaped treatment cavity is composed of two parts that cooperate with each other as a whole, and the two components are sealed with sealing strips at the seams; the treatment cavity The opening and the limb are fixed through a sealed connection assembly. The invention is light, easy to operate in and out of the limbs, completely eliminates the radial pressure, and greatly improves the therapeutic effect.

It has been discovered the BH3-only proapoptotic Bcl-2 proteins like PUMA (the p53 upregulated modulator of apoptosis) can be activated in fibroblast-like synoviocytes present in the joints of subjects with rheumatoid arthritis. This bypasses the p53 apoptotic pathway, which normally clears FLS fomr the joints, but is often defective in arthritis. Suitable therapeutic agents of this invention include gene vectors that cause increased expression of BH3-only proapoptotic proteins in target cells. These agents are formulated in pharmaceutical compositions for administration directly to joint. Reestablishing apoptosis in synoviocytes decreases their pro-inflammatory and destrcutive activity, improving the clinical condition.

The invention discloses an arthritis therapeutic instrument capable of completely adhering joints of different human bodies. The arthritis therapeutic instrument comprises a folding sleeve; magnetic suction plates are vertically arranged at two sides of the folding sleeve; a plurality of fixing blocks are arranged inside the magnetic suction plates at intervals; a sliding ring is arranged in the center of one side, far away from the folding sleeve, of each fixing block; each sliding ring is mutually and rotationally connected with one corresponding fixing block through fixing rods at two sides; and connecting blocks are arranged among the plurality of fixing blocks. According to the invention, surrounding springs are driven to bend, so that one side, close to a diseased joint, of each surrounding spring is compressed, and one side, far away from the diseased joint, of each surrounding spring is expanded; and springs in the connecting blocks are driven to bend, so that the magnetic attraction plates are mutually tensioned. In addition, attachment is kept through pulling force of the surrounding springs, so that the surrounding springs are driven to move when the fixing blocks move;and the rthritis therapeutic instrument has the advantages that the rthritis therapeutic instrument can be mutually attached to the joint, and the position can be adjusted after the rthritis therapeutic instrument is fixed without disassembly.

The invention relates to a biological agent for treating arthritis as well as a preparation method and application of the biological agent. The biological agent is prepared from urinary stem cell exosome rich in miR40-5p. The urinary stem cell exosome suspension rich in miR40-5p is used for joint cavity injection treatment of a patient suffering from knee osteoarthritis, and meanwhile, the mesenchymal stem cells and the miR40-5p are combined to relieve osteoarthritis progress and promote cartilage regeneration, so that the biological hidden danger during stem cell injection treatment and the poor targeting property of miR40-5p injection treatment are avoided; the injection type biological preparation for treating knee osteoarthritis is a novel injection type biological preparation for treating knee osteoarthritis, which is rich in innovation and clinical conversion value.

The invention discloses an intelligent arthritis therapeutic instrument, which comprises a device body and a power interface. One end is fixedly connected with the movable connection block, an electromagnetic therapeutic apparatus is arranged above the movable connection block, one end of the electromagnetic therapeutic apparatus is fixedly connected with the movable connection block, an infrared therapeutic apparatus is arranged inside the device body, and the infrared therapeutic apparatus is fixedly connected with the device body. This kind of intelligent arthritis treatment instrument is equipped with a movable connection block inside, which is movably connected to the inner wall of the device body, and the movable connection block is made of "soft" material, and the movable connection block can be moved. parts, fully fitted on the joints of the human body, so as to provide comprehensive treatment for patients.

The present invention provides with a therapeutic agent for arthritis, which contains a low-molecular-weight FoxM1 inhibitor, e.g., thiostrepton, as an active ingredient. FoxM1 is expressed in an osteoclast progenitor that occurs specifically in an inflamed synovium in arthritis, and is not involved in the function of an osteoclast that is present in the bone marrow in a normal person and is involved in normal bone metabolism. Therefore, arthritis can be prevented and/or treated without any adverse side effect by using a FozM1 inhibitor.

The invention relates to a saussurea involucrata flavonoid composition, which is prepared from the following four components: rutin, myristyl ether, isoquercitrin and luteolin-7-o-glucoside. A large number of animal experiments prove the pharmacodynamic activity of the flavonoid composition provided by the invention, the flavonoid composition can be used for preparing various clinically applied pain relieving and pain easing medicines and arthritis treatment medicines, and compared with a Chinese patent medicine preparation prepared by directly applying saussurea involucrata, the composition has the effects of high pharmacodynamic activity, small clinical dosage, quick response, low side effect and the like. The dosage form of the medicine can be conventional tablets or capsules, and some new dosage forms of the medicine with higher absorptivity or better storability can be prepared according to the characteristics of the medicine components.

The invention discloses application of resveratrol-polylactic acid long-acting nano-microspheres in preparation of an anti-osteoarthritis drug, and belongs to the field of osteoarthritis treatment. The preparation method of the nano-microspheres comprises the following steps of: jointly dissolving resveratrol and polylactic acid in dichloromethane to form an organic phase; mixing the organic phase with a PVA solution I, performing high-speed shearing under an ice bath condition to form an emulsion, then slowly dripping the emulsion into a PVA solution II, performing stirring at a low speed to volatilize an organic solvent, and collecting microspheres; and centrifuging the collected microspheres, discarding the supernate, cleaning the nano-microspheres, and performing freeze-drying to obtain the resveratrol-polylactic acid long-acting nano-microspheres. The preparation method is simple and easy to operate; the stability of the resveratrol-polylactic acid nano-microspheres is improved by optimizing preparation conditions; the resveratrol-polylactic acid nano-microspheres are suitable for industrial popularization and application; and the nano-microspheres can remarkably relieve cartilage injury, synovitis and other symptoms after knee joint cavity injection and can be used for development of drugs for treating knee osteoarthritis.

The invention relates to the technical field of arthritis treatment instruments, and discloses a small portable electrode type infrared blue laser arthritis treatment instrument which comprises a thick rubber pad, a conical hole is formed in the lower end face of the thick rubber pad, a first rotating column and a second rotating column are connected into the thick rubber pad, and a round hole isformed in the thick rubber pad. A swing rod is connected to the outer side of the first rotating column, a volute spiral spring is connected to the outer side of the second rotating column, a cloth belt is connected to the outer end of the volute spiral spring, and a guide column is arranged in the thick rubber pad. By pulling the cloth belt, the cloth belt drives the volute spiral spring to contract, the cloth belt extrudes the swing rod, the swing rod extrudes the compression spring through the first rotating column, and the tension between the cloth belt and the volute spiral spring is different, so that the deviation angles of the swing rod are different, the swing rod drives the laser lamp at the lower end of the swing rod to change the angle, and the structure achieves the effect ofadjusting the laser angle. Therefore, the problem that the existing arthritis treatment equipment cannot save the laser angle is solved.

The invention discloses a cartilago articularis quantitative imaging analysis method based on T2 mapping and T1 rho. The cartilago articularis quantitative imaging analysis method comprises the following steps: 1, carrying out MRI scanning; 2, dividing a lower end area of the femur; 3, conducting image evaluation; 4, measuring data; 5, carrying out statistical analysis, wherein the scanning sequence and parameters of the MRI scanning comprise conventional scanning and non-conventional scanning. According to the articular cartilage quantitative imaging analysis method based on T2 mapping and T1rho, knee osteoarthritis is a multi-factor disease, many patients suffer from the disease, and the social burden is heavy. A new strategy for treating knee osteoarthritis is early discovery and minimally invasive treatment, T2 and T1 rho values can be measured through magnetic resonance T2 mapping and T1 rho imaging technologies, change of an articular cartilage biochemical structure is reflectedfrom the molecular level before morphological change of articular cartilage, high sensitivity and specificity are achieved, and early diagnosis and treatment can be conducted on early OA.

The invention relates to an application of a saussurea involucrata flavonoid composition in preparation of a pharmaceutical preparation for treating arthritis diseases, the saussurea involucrata flavonoid composition comprises four components, and the four components are rutin, myristyl ether, isoquercitrin and luteolin-7-o-glucoside respectively. A large number of animal experiments prove the pharmacodynamic activity of the flavonoid composition provided by the invention, the flavonoid composition can be used for preparing various clinically applied pain relieving and pain easing medicines and arthritis treatment medicines, and compared with a Chinese patent medicine preparation prepared by directly applying saussurea involucrata, the composition has the effects of high pharmacodynamic activity, small clinical dosage, quick response, low side effect and the like. The dosage form of the medicine can be conventional tablets or capsules, and some new dosage forms of the medicine with higher absorptivity or better storability can be prepared according to the characteristics of the medicine components.

The invention relates to an application of a saussurea involucrata flavonoid composition in preparation of a pain relieving and pain easing pharmaceutical preparation, the saussurea involucrata flavonoid composition comprises four components, and the four components are rutin, myristyl ether, isoquercitrin and luteolin-7-o-glucoside respectively. A large number of animal experiments prove the pharmacodynamic activity of the flavonoid composition provided by the invention, the flavonoid composition can be used for preparing various clinically applied pain relieving and pain easing medicines and arthritis treatment medicines, and compared with a Chinese patent medicine preparation prepared by directly applying saussurea involucrata, the composition has the effects of high pharmacodynamic activity, small clinical dosage, quick response, low side effect and the like. The dosage form of the medicine can be conventional tablets or capsules, and some new dosage forms of the medicine with higher absorptivity or better storability can be prepared according to the characteristics of the medicine components.

The invention relates to the technical field of arthritis treatment devices, in particular to a treatment device and method for diagnosis and treatment of rheumatoid arthritis through traditional Chinese medicine external therapy. The treatment device comprises a sealing box, a smoke filtering assembly is arranged in the sealing box, a lifting plate is arranged above the sealing box, and a set of adjusting assemblies are arranged at the top of the lifting plate; according to the moxibustion device, under the action of the automatic filling assembly, moxa blocks can be automatically filled in the moxibustion process of a user, the moxibustion treatment process cannot be interrupted, the risk that the user is scalded can be effectively reduced, the moxibustion treatment efficiency is improved, and the moxibustion device is suitable for popularization and application. Under the action of the ash removal assembly, moxa ash on the surface of the moxa block can be automatically removed, and the situation that the surface of the moxa block is covered with the moxa ash, the surface temperature of the moxa block is lowered, and the moxibustion treatment effect is affected is prevented.

The invention relates to an extraction method of a saussurea involucrata flavonoid composition. The extraction method comprises the following steps: (1) alcohol extraction; (2) fine extraction; and (3) freeze-drying. According to the extraction method disclosed by the invention, the saussurea involucrata flavonoid composition containing four components, namely rutin, myristyl ether, isoquercitrin and luteolin-7-o-glucoside, can be obtained, research finds that the flavonoid composition has pharmacodynamic activity, can be used for preparing various clinically applied pain relieving and easing medicines and arthritis treatment medicines, and has the effects of high pharmacodynamic activity, small clinical dosage, quick effect, low side effect and the like compared with a Chinese patent medicine preparation prepared by directly applying saussurea involucrata.